This clinical trial compares a new smoking cessation smartphone application (app) (IndigeQuit) to an existing smarphone app (National Cancer Institute \[NCI\] QuitGuide) for helping American Indians and Alaska Natives (AI/ANs) quit smoking. Compared to other racial/ethnic groups, AIANs have 6 times higher rates of developing smoking-related cancers, including lung cancer. Commercial cigarette smoking accounts for half of all deaths among AIANs nationwide. AIANs' often lack of access to smoking cessation interventions, which may be due to inequities in the healthcare system, lack of health insurance, living in rural areas, systemic racism, and historical trauma. There is also a lack of effective smoking cessation interventions for AIANs. Smartphone apps have the potential to deliver a low-cost smoking cessation intervention with wide reach to AIANs. Apps require no in-person delivery and no provider training, do not require integration into complex hospital systems, can be freely accessed on an app store, and are available at any time and any place. IndigeQuit is a behavioral intervention designed to help adults stop smoking by teaching skills for coping with smoking urges, staying motivated, and preventing relapse. The IndigeQuit app intervention may be more effective than the currently available NCI QuitGuide app at helping AIANs quit smoking.
Self-identify as American Indian or Alaska Native, either alone or in combination with other races
Age 18 and older
Has smoked daily for the past year
Interest in quitting smoking within the next 30 days
Currently (i.e., within past 30 days) using other smoking cessation behavioral interventions
Has participated in our prior research trials
Has used the National Cancer Institute's (NCI's) QuitGuide app
Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization
Parallel
Biospecimen Collection
Procedure/SurgeryAncillary studies
Smoking Cessation Intervention
BehavioralUse IndigeQuit smartphone app
Smoking Cessation Intervention
BehavioralUse NCI QuitGuide smartphone app
Survey Administration
Other interventionAncillary studies
30-day point prevalence abstinence (PPA)
Will be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.
30-day PPA
Will be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.
Self-reported 24-hour PPA
A secondary definition of cessation will include self-reported abstinence from cigarettes and all other commercial nicotine-containing tobacco products (i.e., e-cigarettes or vaping, chewing tobacco, snus, hookahs, cigars, cigarillos, tobacco pipes, kreteks). Will be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.
Self-reported 7-day PPA
A secondary definition of cessation will include self-reported abstinence from cigarettes and all other commercial nicotine-containing tobacco products (i.e., e-cigarettes or vaping, chewing tobacco, snus, hookahs, cigars, cigarillos, tobacco pipes, kreteks). Will be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.
Click on the lead sponsor to view all of their trials.
Fred Hutchinson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
